Evidence map›Paper›PMID 42243117›Full record

ArticleNature communications2026

CYLD-mediated lysine63 deubiquitination regulates synaptic transmission and autophagy to mitigate age-related sequelae.

Aggeliki Sotiriou, Georgios Konstantinidis, Nektarios Tavernarakis

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aggeliki Sotiriou *Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece.ORCID http://orcid.org/0000-0003-2970-6018
Georgios Konstantinidis *Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece.ORCID http://orcid.org/0000-0002-9306-2483
Nektarios TavernarakisInstitute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece. tavernarakis@imbb.forth.gr.ORCID http://orcid.org/0000-0002-5253-1466

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
European Commission (EC) CHAngeing-101087071NIH HHS P40 OD010440
6 · The paper itself

Abstract

Lysine63 polyubiquitination is a prevalent post-translational modification in the central nervous system. Deficiency of CYLD, a lysine63-specific deubiquitinase, is linked to synaptic dysfunction and neurodegenerative disorders. However, our understanding of how CYLD contributes to the manifestation of neuronal deficits, particularly in the context of ageing, remains limited. Here, we report that CYLD-1 is essential for physiological lifespan in the nematode Caenorhabditis elegans. Neuronal CYLD-1 supports cholinergic neurotransmission and GABAergic synapse integrity, ensuring intact locomotory capacity, as well as learning and memory competence. Specifically, the deubiquitinase activity of CYLD-1 is necessary for upholding cholinergic neurotransmission and lifespan. We further show that CYLD-1 regulates autolysosomal and lysosomal network organisation in neurons and peripheral tissues in vivo. Our work unveils a crucial role of CYLD-1 in optimizing neural activity and behavioural outcomes, to improve organismal fitness and survival.

Indexed as

AgingAutophagyCaenorhabditis elegansCaenorhabditis elegans ProteinsDeubiquitinating Enzyme CYLDLysineSynaptic TransmissionAnimalsLongevityLysosomesNeuronsUbiquitinationCaenorhabditis elegans ProteinsDeubiquitinating Enzyme CYLDLysine

Identifiers

PMID42243117
PMCPMC13396389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.